A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil

International Journal of Geriatric Psychiatry

Volumn 19, Issue 1, 2004, Pages 9-18

  Finkel, Sanford I ^a,g   Mintzer, Jacobo E ^b   Dysken, Maurice ^c   Krishnan, K R R ^d   Burt, Tal ^e,h   McRae, Thomas ^f  

^a The University of Chicago   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Geriatric Institute   (United States)

^h NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Antidepressive agents; Cholinesterase inhibitors; Donepezil; Sertraline

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIULCER AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; DONEPEZIL; HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SERTRALINE; THYROID HORMONE;

ADD ON THERAPY; ADULT; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BODY WEIGHT; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HALLUCINATION; HEMODYNAMIC PARAMETERS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; MULTICENTER STUDY; NERVOUSNESS; NEUROPSYCHOLOGICAL TEST; NEUROSIS; OUTCOMES RESEARCH; OUTPATIENT; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

AGED; ALZHEIMER DISEASE; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; BEHAVIORAL SYMPTOMS; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 0842325104     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.998     Document Type: Article

References (45)

1. Bass DM, McClendon MJ, Deiming GT, Mukherjee S. 1994. The diagnosed mental impairment of family caregiving strain. J Gerontology 49: 5146-5155.
2. Borson S, Raskind MA. 1997. Clinical features and phamacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology 48 (5 Suppl. 6): S17-S24.
3. Burke WJ, Dewan V, Wengel SP, Roccaforte WH, Nadolny GC, Folks DG. 1997. The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatr Psychiatry 12: 519-525.
4. Cadoret R, Leve LD, Devor E. 1997. Genetics of aggressive and violent behavior. Psychiatr Clin North Am 20: 301-322.
5. Coccaro EF, Kavoussi RJ, Trestman RL, Gabriel SM, Cooper TB, Siever LJ. 1997. Serotonin function in human subjects: Intercorrelations among central 5-HT indices and aggressiveness. Psychiatry Res 73: 1-14.
6. Cohen-Mansfield J, Marx MS, Rosenthal AS. 1989. A description of agitation in a nursing home. J Gerontology 44, M77-M84.
7. Cohen-Mansfield J. 1995. Assessment of disruptive behavior/agitation in the elderly: Function, methods, and difficulties. J Geriatr Psychiatry Neurol 8: 52-60.
8. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. 1994. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
9. DeDeyn PP, Rabheru K, Rasmussen A, et al 1999. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology 53: 946-955.
10. Devanand DP, Marder K, Michaels KS, et al. 1998. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 155: 1512-1520.
11. Dringenberg HC. 2000. Alzheimer's disease: More than a 'cholinergic disorder - Evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 115: 235-249.
12. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. 2001. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57: 613-620.
13. Filley CM, Price BH, Nell V, et al. 2001. Toward an understanding of violence: Neurobehavioral aspects of unwarranted physical aggression: Aspen Neurobehavioral Conference consensus statement. Neuropsychiatry Neuropsychol Behav Neurol 14: 1-14.
14. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. 1996. Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 8(Suppl. 3): 497-500.
15. Finkel SI, Lyons JS, Anderson RL, et al. 1995. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 10: 129-136.
16. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res. 12: 189-198.
17. Guy W. 1967. ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education, and Welfare; NIMH: Rockville, MD; 217-222.
18. Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychology 6: 278-296.
19. Hamilton M. 1982. Use of rating scales in geriatric patients. Gerontology 28(Suppl. 2): 42-48.
20. Harwood DG, Barker WW, Ownby RL, Duara R. 2000. Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer's disease. Int J Geriatr Psychiatry 15: 393-400.
21. Hughes CP, Berg L, Danziger WL, Cohen LA, Martin RL. 1982. A new clinical scale for the staging of dementia. Br J Psychiatry 140: 566-572.
22. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. 1999. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 60: 107-115.
23. Lanctot KL, Best TS, Mittmann N, et al. 1998. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 59: 550-561.
24. Lanctot KL, Herrmann N, Mazzotta P. 2001. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 13: 5-21.
25. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. 1996. Longitudinal assessment of symptoms of depression, agitation and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 153, 1438-1443.
26. Lyketsos CG, Sheppard JM, Steele CE, et al. 2000. Randomized, placebo-controlled, double-blind clinical trial of sertaline in the treatment of depression complicating Alzheimer's disease: Initial results from the Depression in Alzheimer's Disease Study. Am J Psychiatry 157: 1686-1689.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
28. Mega MS, Cummings JL, Fiorello T, Gornbein J. 1996. The spectrum of behavioral changes in Alzheimer's disease. Neurology 46: 130-135.
29. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. 1999. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 56: 1388-1393.
30. Mintzer JE. 2001. Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. J Clin Psychiatry 62(Suppl. 21): 23-25.
31. Nyth AL, Gottfries CG. 1990. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A nordic multicentre study. Br J Psychiatry 157: 894-901.
32. O'Donnell BF, Drachman DA, Barnes HJ, Peterson KE, Swearer JM, Lew RA. 1992. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 5: 45-52.
33. Pollock BG, Mulsant BH, Rosen J, et al. 2002. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 159: 460-465.
34. Pollock BG, Mulsant BH, Sweet R, et al. 1997. An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Am J Geriatr Psychiatry 5: 70-78.
35. Porsteinsson AP, Tariot PN, Erb R, et al. 2001. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 9: 58-66.
36. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. 1987. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry 48(Suppl.): 9-15.
37. Rosen WG, Mohs RD, Davis KL. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364.
38. Steele C, Rovner B, Chase GA, Folstein M. 1990. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 147: 1049-1051.
39. Street JS, Clark WS, Gannon KS, et al. 2000. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 57: 968-976.
40. Suh GH, Shah A. 2001. A review of the epidemiological transition in dementia - Cross-national comparisons of the indices related to Alzheimer's disease and vascular dementia. Acta Psychiatr Scand 104: 4-11.
41. Tariot PN, Erb R, Podgorski C, et al. 1998. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 155: 54-61.
42. Tariot PN, Ryan JM, Porsteinsson AP, Loy R, Schneider L. 2001. Pharmacologic therapy for behavioral symptoms of Alzheimer's disease. Clin Geriatr Med 17: 359-376.
43. Teri L, Borson S, Kiyak HA, Yamagishi M. 1989. Behavioral disturbance, cognitive dysfunction, and functional skill. Prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc 37: 109-116.
44. Volicer L, Direnfeld LK, Freedman M, Albert ML, Langlias PJ, Bird ED. 1985. Serotonin and 5-hydroxyindoleacetic acid in CSF: Difference in Parkinson's disease and dementia of the Alzheimer's type. Arch Neurol 42: 127-129.
45. Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetik DA. 2000. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry 61: 487-492.